Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.53 |
| ▸ | DRD4 | P21917 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7310845 | 0.88 | NPC1 (0.48) | NPC1RAB9AL3MBTL1 | |
| SCHEMBL13711930 | 0.88 | NPC1 (0.54) | NPC1RAB9AL3MBTL1ACE | |
| SCHEMBL24582713 | 0.87 | NPC1 (0.54) | NPC1RAB9AL3MBTL1ACE | |
| SCHEMBL1000224 | 0.87 | NPC1 (0.54) | NPC1RAB9AL3MBTL1ACE | |
| SCHEMBL3208272 | 0.87 | NPC1 (0.54) | NPC1RAB9AL3MBTL1ACE | |
| SCHEMBL7036798 | 0.87 | PTPN1 (0.52) | NPC1RAB9AL3MBTL1NPSR1 | |
| SCHEMBL7038704 | 0.85 | LMNA (0.53) | — | |
| SCHEMBL12474768 | 0.84 | NPC1 (0.51) | NPC1RAB9AL3MBTL1ACE | |
| SCHEMBL6973564 | 0.84 | PSEN1 (0.48) | NPC1RAB9A | |
| SCHEMBL4434465 | 0.84 | NPC1 (0.46) | NPC1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122666-B2 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-10-17 | — | — | US | disclosed |
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1377577-B1 | PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES | SANKYO CO (JP) | 2006-06-14 | — | — | EP | disclosed |
| US-20050283006-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2005-12-22 | — | — | US | disclosed |
| US-20050159444-A1 | Bicyclic unsaturated tertiary amine compounds | SANKYO COMPANY, LIMITED (JP) | 2005-07-21 | — | — | US | disclosed |
| EP-1541571-A1 | BICYCLIC UNSATURATED TERTIARY AMINE COMPOUND | Sankyo Company, Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-20040054173-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1377577-A1 | PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES | Sankyo Company Limited (JP) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002057264-A1 | PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES | SANKYO COMPANY LIMITED (JP) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159444-A1 | Bicyclic unsaturated tertiary amine compounds | IL1B, IL1A, STAT6 | DRD2 775/4885DRD4 1419/4885NPC1 1071/4885 |
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, IL1A, IL1B | DRD2 1496/4885DRD4 2433/4885NPC1 4527/4885 |
| US-20050283006-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, CNKSR1, IL1A | DRD2 812/4885DRD4 1476/4885NPC1 4624/4885 |
| US-20040054173-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, IL1B, IL1A | DRD2 905/4885DRD4 1488/4885NPC1 4253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.